Fresenius Medical Care AG & Co. (NYSE:FMS) had its price objective reduced by SunTrust Banks to $46.00 in a report issued on Tuesday, The Fly reports. SunTrust Banks currently has a buy rating on the stock. SunTrust Banks also issued estimates for Fresenius Medical Care AG & Co.’s Q1 2019 earnings at $0.57 EPS, Q2 2019 earnings at $0.63 EPS, Q3 2019 earnings at $0.68 EPS, Q4 2019 earnings at $0.73 EPS, FY2019 earnings at $2.61 EPS and FY2020 earnings at $2.84 EPS.

FMS has been the topic of several other reports. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a sell rating to a hold rating in a research note on Friday, August 17th. HSBC upgraded Fresenius Medical Care AG & Co. from a hold rating to a buy rating in a research note on Tuesday, August 28th. Royal Bank of Canada restated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research note on Friday, August 17th. ValuEngine cut Fresenius Medical Care AG & Co. from a hold rating to a sell rating in a research note on Wednesday, October 17th. Finally, UBS Group upgraded Fresenius Medical Care AG & Co. from a neutral rating to a buy rating and set a $82.00 price objective on the stock in a research note on Friday, October 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. Fresenius Medical Care AG & Co. has an average rating of Hold and a consensus price target of $62.00.

NYSE FMS opened at $37.53 on Tuesday. Fresenius Medical Care AG & Co. has a 12-month low of $37.47 and a 12-month high of $57.94. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.24 and a quick ratio of 1.00. The firm has a market capitalization of $23.91 billion, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 1.73 and a beta of 1.10.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.11. Fresenius Medical Care AG & Co. had a net margin of 11.71% and a return on equity of 10.87%. The business had revenue of $4.72 billion during the quarter. On average, sell-side analysts expect that Fresenius Medical Care AG & Co. will post 2.52 earnings per share for the current year.

A number of large investors have recently modified their holdings of FMS. Acadian Asset Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth $106,000. Destination Wealth Management bought a new stake in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth $158,000. Mount Yale Investment Advisors LLC bought a new stake in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth $192,000. Intercontinental Wealth Advisors LLC bought a new stake in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth $203,000. Finally, HBK Sorce Advisory LLC bought a new stake in shares of Fresenius Medical Care AG & Co. during the 3rd quarter worth $209,000. Institutional investors and hedge funds own 2.53% of the company’s stock.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Featured Article: Buyback For Investors Defined

The Fly

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.